Asset Details
Do you wish to reserve the book?
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
Do you wish to request the book?
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
2021
Overview
Background: Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis. Methods: We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay. Results: We found significant decreases in severity scores of liver disease [LSM ( q -value < 0.001), HVPG ( q -value = 0.011), and CTP ( q -value = 0.045)] and plasma biomarkers [LBP ( q -value < 0.001), IP-10 ( q -value < 0.001), IL-8 ( q -value < 0.001), IL-18 ( q -value < 0.001), IL-1RA ( q -value = 0.013), OPG ( q -value < 0.001), sVCAM-1 ( q -value < 0.001), sICAM-1 ( q -value < 0.001), PAI-1 ( q -value = 0.001), and VEGF-A ( q -value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP ( q -value < 0.001), IP-10 ( q -value < 0.001), MCP-1 ( q -value = 0.008), IL-8 ( q -value < 0.001), IL-18 ( q -value < 0.001), OPG ( q -value = 0.004), sVCAM-1 ( q -value < 0.001), sICAM-1 ( q -value < 0.001), and PAI-1 ( q -value = 0.002). For CTP values, we found significant positive associations with IP-10 ( q -value = 0.010), IL-6 ( q -value = 0.010), IL-1RA ( q -value = 0.033), and sICAM-1 ( q -value = 0.010). Conclusion: The HCV eradication with all-oral DAAs in HIV/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values.
Publisher
Frontiers Media SA,Frontiers Media S.A
